Public Sector Pension Investment Board lifted its stake in shares of Bausch Health Companies Inc. (NYSE:BHC – Free Report) by 7.3% during the first quarter, Holdings Channel.com reports. The firm owned 602,663 shares of the company’s stock after acquiring an additional 41,211 shares during the period. Public Sector Pension Investment Board’s holdings in Bausch Health Companies were worth $4,876,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Steward Financial Group LLC acquired a new position in Bausch Health Companies during the 4th quarter worth approximately $40,000. Acrisure Capital Management LLC acquired a new position in shares of Bausch Health Companies during the fourth quarter worth approximately $70,000. Oakworth Capital Inc. lifted its holdings in shares of Bausch Health Companies by 22.9% in the 1st quarter. Oakworth Capital Inc. now owns 9,952 shares of the company’s stock worth $81,000 after purchasing an additional 1,852 shares in the last quarter. FMR LLC increased its stake in Bausch Health Companies by 58.3% during the 2nd quarter. FMR LLC now owns 10,057 shares of the company’s stock valued at $84,000 after purchasing an additional 3,703 shares in the last quarter. Finally, NewEdge Advisors LLC acquired a new position in Bausch Health Companies during the second quarter worth $95,000. 74.56% of the stock is currently owned by institutional investors and hedge funds.
Bausch Health Companies Trading Up 1.4 %
Shares of BHC stock opened at $8.46 on Monday. Bausch Health Companies Inc. has a one year low of $5.57 and a one year high of $10.23. The firm has a 50-day moving average of $8.60 and a 200-day moving average of $8.03. The company has a current ratio of 1.12, a quick ratio of 0.81 and a debt-to-equity ratio of 74.20.
Wall Street Analysts Forecast Growth
BHC has been the subject of a number of analyst reports. StockNews.com started coverage on shares of Bausch Health Companies in a report on Thursday, August 17th. They set a “hold” rating for the company. TD Cowen downgraded Bausch Health Companies from an “outperform” rating to a “market perform” rating in a research note on Friday, June 16th. Jefferies Financial Group increased their price objective on Bausch Health Companies from $7.00 to $9.50 in a research note on Monday, May 22nd. Finally, Royal Bank of Canada lifted their target price on Bausch Health Companies from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Monday, July 24th.
Bausch Health Companies Profile
Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
- Five stocks we like better than Bausch Health Companies
- The How and Why of Investing in Large-Cap Stocks
- MarketBeat Week in Review – 8/28 – 9/1
- Consumer Staples Stocks, Explained
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Invest in Fertilizer
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.